![[Cory Franklin] Try to adapt to weather extremes](/_next/image?url=https%3A%2F%2Fwimg.heraldcorp.com%2Fnews%2Fcms%2F2025%2F08%2F03%2Fnews-p.v1.20250803.d52c7ce8fd294cb3b62c18cc224b3831_T1.jpg&w=3840&q=100)
[Cory Franklin] Try to adapt to weather extremes
But no less important are environmental deaths, specifically those related to hot and cold weather, which are rarely cited. The US figures are far more impressive than those of the rest of the industrialized world, and it is inarguable that this country does a much better job of preventing heat and cold deaths than Europe does.
First, heat deaths: Comparisons of heat deaths between countries are limited because numbers vary according to how heat deaths are defined, the differences in weather and patient characteristics in various countries, and the sources of the data. The numbers here are a compendium from several sources, including Lancet, Nature and several public health and weather websites; mileage may vary.
Taking all this into account, the difference in annual heat deaths between Europe and the US is surprising: In the 21st century, European heat deaths on average range from 60 to 200 per 1 million people annually, while American heat deaths average about three to eight per million annually. This means, conservatively, each year, perhaps 20 times as many people die of the heat in Europe as in the US. A graphic example: During the recent European heat wave that began in May, one country, Spain, experienced 1,180 deaths in only two months.
The data from deaths due to cold weather are even more sobering. Even with a warming Earth, cold continues to kill more people than heat in most parts of the world where there is any kind of cold winter. In Europe, there have been 300 to 500 deaths per million due to cold annually in the past three decades, while in the US, the number of deaths from cold is in the range of 10 per million. So a conservative estimate would be that for every person who dies as a result of cold weather in the US, at least 30 die in Europe.
When deaths from heat and cold are combined, Europe has close to 50 times as many deaths as the US -- as many as 250,000 to 500,000 more deaths every year. Over a decade, this means several million more people die from heat and cold in Europe than die in the US from those causes. A comparison of the annual numbers shows that the difference in environmental deaths easily surpasses the much more widely reported firearm death comparison. The US has nearly 50,000 firearm deaths annually, and Europe has under 10,000, so the difference in firearm deaths, roughly 40,000, is about 1/10th of the difference in environmental deaths.
Why is there such a difference in environmental deaths between the US and Europe? The consensus among experts regarding heat deaths is the ubiquity of air conditioning in the US and the relative paucity in Europe. (The majority of deaths in Spain during the May-June heat wave were in the north of the country, where air conditioning is uncommon compared to the south.) Besides providing comfort, air conditioning saves lives -- often many -- especially if air conditioning could be made more available in the Global South, where there are even more deaths due to hot weather.
Despite the consensus, some environmentalists want to limit air conditioning, citing increased electricity use and carbon dioxide production, which will aggravate greenhouse gas emissions. (In 2022, Spain was one of the countries that put restrictions on air conditioning.) The response to climate change must involve a combination of mitigation, such as reducing levels of heat-trapping greenhouse gases and adaptation -- that is, adapting to the consequences of a warming environment.
According to Hannah Ritchie, deputy editor of the Our World in Data website, air conditioning currently accounts for about 7 percent of global electricity use and 3 percent of carbon dioxide emissions -- not negligible but certainly not exorbitant considering how many lives cooling technology saves. While worldwide air conditioning use is expected to increase in the next decade, so is the efficiency of air conditioning units. Air conditioning represents one of the most effective and lifesaving methods of adaptation to a changing climate.
The reasons for increased cold-weather deaths in Europe relative to the US are harder to divine, but likely include the ubiquity of older homes with poorer insulation throughout Europe. Outside of Scandinavia, there may be less preparedness and an aging population more vulnerable to cold weather snaps on the European continent.
Human-made efforts to reduce greenhouse gases are essential, but human-made efforts to adapt to weather extremes would have lifesaving consequences more immediately.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Korea Herald
3 days ago
- Korea Herald
Dozens killed seeking aid in Gaza as Israel weighs further military action
At least 38 Palestinians were killed overnight and into Wednesday in the Gaza Strip while seeking aid from UN convoys and sites run by an Israeli-backed American contractor, according to local health officials. The Israeli military said it had fired warning shots when crowds approached its forces. Another 25 people, including several women and children, were killed in Israeli airstrikes, according to local hospitals in Gaza. The military said it only targets Hamas militants. The latest deaths came as Prime Minister Benjamin Netanyahu was expected to announce further military action — and possibly plans for Israel to fully reoccupy Gaza. Experts say Israel's ongoing military offensive and blockade are already pushing the territory of some 2 million Palestinians into famine. A new UN report said only 1.5 percent of Gaza's cropland is accessible and undamaged. Another escalation of the nearly 22-month war could put the lives of countless Palestinians and around 20 living Israeli hostages at risk, and would draw fierce opposition both internationally and within Israel. Netanyahu's far-right coalition allies have long called for the war to be expanded, and for Israel to eventually take over Gaza, relocate much of its population and rebuild Jewish settlements there. US President Donald Trump, asked by a reporter Tuesday whether he supported the reoccupation of Gaza, said he wasn't aware of the 'suggestion' but that 'it's going to be pretty much up to Israel.' Of the 38 Palestinians killed while seeking aid, at least 28 died in the Morag Corridor, an Israeli military zone in southern Gaza where UN convoys have been repeatedly overwhelmed by looters and desperate crowds in recent days, and where witnesses say Israeli forces have repeatedly opened fire. The Israeli military said troops fired warning shots as Palestinians advanced toward them, and that it was not aware of any casualties. Nasser Hospital, which received the bodies, said another four people were killed in the Teina area, on a route leading to a site in southern Gaza run by the Israeli-backed Gaza Humanitarian Foundation, an American contractor. The Al-Awda Hospital said it received the bodies of six people killed near a GHF site in central Gaza. GHF said there were no violent incidents at or near its sites, and that the one in central Gaza was not open on Wednesday. It said the violence may have been related to the chaos around UN convoys. Two of the Israeli airstrikes hit Gaza City, in the north of the territory, killing 13 people there, including six children and five women, according to the Al-Ahli Hospital, which received the bodies. The Israeli military says it only targets militants and blames civilian deaths on Hamas because its militants are entrenched in heavily populated areas. Israel facilitated the establishment of four GHF sites in May after blocking the entry of all food, medicine and other goods for 2 1/2 months. Israeli and US officials said a new system was needed to prevent Hamas from siphoning off humanitarian aid. The UN, which has delivered aid to hundreds of distribution points across Gaza throughout the war when conditions allow, has rejected the new system, saying it forces Palestinians to travel long distances and risk their lives for food, and that it allows Israel to control who gets aid, potentially using it to advance plans for further mass displacement. The UN human rights office said last week that some 1,400 Palestinians have been killed seeking aid since May, mostly near GHF sites but also along UN convoy routes where trucks have been overwhelmed by crowds. It says nearly all were killed by Israeli fire. This week, a group of UN special rapporteurs and independent human rights experts called for the GHF to be disbanded, saying it is 'an utterly disturbing example of how humanitarian relief can be exploited for covert military and geopolitical agendas in serious breach of international law.' The experts work with the UN but do not represent the world body. The GHF called their statement 'disgraceful,' and urged the UN and other aid groups to work with it 'to maximize the amount of aid being securely delivered to the Palestinian people in Gaza.' The Israeli military says it has only fired warning shots when crowds threatened its forces, and GHF says its armed contractors have only used pepper spray and fired into the air on some occasions to prevent deadly crowding at its sites. Israel's air and ground war has destroyed nearly all of Gaza's food production capabilities, leaving its people reliant on international aid. A new report by the UN's Food and Agriculture Organization and the UN satellite center found that just 8.6 percent of Gaza's cropland is still accessible following sweeping Israeli evacuation orders in recent months. Just 1.5 percent is accessible and undamaged, it said. The military offensive and a breakdown in security have made it nearly impossible for anyone to safely deliver aid, and aid groups say recent Israeli measures to facilitate more assistance are far from sufficient. Hospitals recorded four more malnutrition-related deaths over the last 24 hours, bringing the total to 193 people, including 96 children, since the war began in October 2023, according to the Gaza Health Ministry. Jordan said Israeli settlers blocked roads and hurled stones at a convoy of four trucks carrying aid bound for Gaza after they drove across the border into the Israeli-occupied West Bank. Israeli far-right activists have repeatedly sought to halt aid from entering Gaza. Jordanian government spokesperson Mohammed al-Momani condemned the attack, which he said had shattered the windshields of the trucks, according to the Jordanian state-run Petra News Agency. The Israeli military said security forces went to the scene to disperse the gathering and accompanied the trucks to their destination. Hamas-led militants killed some 1,200 people, mostly civilians, in the Oct. 7 attack and abducted another 251. Most of the hostages have been released in ceasefires or other deals. Of the 50 still held in Gaza, around 20 are believed to be alive. Israel's retaliatory offensive has killed over 61,000 Palestinians, according to Gaza's Health Ministry, which does not say how many were fighters or civilians but says around half were women and children. It is part of the now largely defunct Hamas-run government and staffed by medical professionals. The UN and independent experts consider it the most reliable source for the number of war casualties. (AP)

Korea Herald
5 days ago
- Korea Herald
iNtRON Bio, Demonstrated Toxin-Neutralizing Effect of IMPA™ Phage Engineering Technology in Colorectal Cancer Model and Completed the US Patent Application
• Successful validation of payloaded anti-colibactin toxin phage using IMPA ™ technology • Demonstrated ' Dual-target Therapeutic Strategy ' by bacterial eradication and toxin neutralization • Filed the US patent application for the candidate substance and preclinical studies including PoC underway BOSTON and SEOUL, South Korea, Aug. 5, 2025 /PRNewswire/ -- Recently, a specific genotype of E. coli that may cause colorectal cancer has been detected in commonly eaten leafy vegetables such as lettuce, raising consumer concerns. Among these strains, pks+ E. coli is of particular concern. This bacterium produces a toxic substance in the intestine that causes DNA damage (ICLs, Interstrand Cross-Links), which leads to DSBs (Double Strand Breaks), and has been shown in numerous studies, including Nature (2023), to increase the risk of colorectal cancer over time. Amid this situation, as an innovative bacteriophage technology development company, iNtRON Bio proposes a new possibility for microbiome-based anticancer drugs in treating colorectal cancer—considered a hard-to-treat disease—by applying our phage engineering technology called IMPA™. iNtRON Bio has been developing PHAGERIA Ⓡ, an immunotherapeutic targeting gut bacteria, and through the IMPA™ phage engineering technology developed in-house, iNtRON Bio has secured a new drug candidate payloaded with a substance that effectively eliminates colibactin ,a major causative agent of colorectal cancer and have filed a related US patent application. The phage engineering technology IMPA™ (Intelligent Modular Phage Assembly) was formerly known as the "robot bacteriophage." With the recent US patent application, it was named to clearly reflect the function as a technology for engineering modular phages (mock-up phages) that can carry therapeutic payloads. This achievement is the result of combining transposon mutagenesis, CRISPR/Cas-based forward/reverse genetics, and AI-driven analysis capabilities to explore the possibility of delivering various functional payloads. In particular, it is highly significant that iNtRON Bio successfully loaded a payload targeting colibactin ,deeply involved in colorectal cancer, onto the surface of the phage and, for the first time globally, confirmed its effectiveness. In other words, iNtRON Bio has demonstrated a dual-targeting therapeutic approach that not only eliminates pks+ E. coli, which is a main cause of colorectal cancer, but also neutralizes the toxin secreted by this bacterium. This includes verifying colibactin's role in cancer development, confirming the suppressive effect of modular phage on colorectal cancer, and proving the phage's colibactin-degrading ability—resulting in successful proof-of-concept studies and related patent acquisition. Simply put, the core of this development is that a colibactin-degrading protein was applied as a payload on the phage's protein shell, known as the capsid. Like a precision-guided missile with a warhead, the engineered phage specifically infects pks+ E. coli, kills the bacteria, and at the same time removes the colibactin toxin already secreted by the bacterium using the enzyme carried in the capsid—offering a dual therapeutic effect. Recently, the field of bacteriophage engineering is gaining attention globally. IMPA™ technology is not only a unique platform technology differentiated from other companies, but also serves as strong evidence that it can function as an actual drug delivery platform beyond simple research use. It is encouraging that iNtRON Bio's research has overcome key limitations of conventional phage-based technologies, such as decreased payload activity and phage structural instability when therapeutic substances are loaded. By confirming that the payload retains its original function, iNtRON Bio has demonstrated that it has successfully overcome high technical hurdles. The engineered phages are not merely for research purposes but were selected and validated through multiple tests with real-world and human applications in mind. iNtRON Bio has applied an advanced AI-driven optimization platform technology, refined it with great care, and plan to extend its application to other development fields for ongoing innovation. This achievement is not only a remarkable advancement in phage engineering technology but will also become a driving force for discovering innovative microbiome drug candidates through integration with other phage-based platform technologies of iNtRON Bio. It will proceed smoothly with preclinical studies including proof-of-concept (PoC) testing for combination effects with existing colorectal cancer therapies. In addition, IMPA™ phage engineering technology will be applied more broadly to ADC drug development, anti-cancer agent, and vaccines, as iNtRON Bio continues to strengthen our global technological competitiveness in these fields.


Korea Herald
6 days ago
- Korea Herald
Minaris Advanced Therapies Opens New State-of-the-Art GMP Facility to Support Global Cell and Gene Therapy Growth
MUNICH, Aug. 4, 2025 /PRNewswire/ -- Minaris Advanced Therapies, a leading global contract development and manufacturing organization and testing provider, has announced the opening of its new GMP manufacturing facility in Munich, Germany. The facility, located in Taufkirchen, strengthens Minaris' global manufacturing network and reinforces its position as a trusted partner in advancing cutting-edge therapies from concept to commercialization. Minaris' new facility builds on over 10 years of experience in both the clinical and commercial manufacture of advanced therapies. The facility is built to support technology transfer of commercial advanced therapies into Europe. The new facility enabled the consolidation of process and analytical development, and all the legacy manufacturing operations onto a single site. Located just minutes from the Munich International Airport, the new facility offers a strategic logistical advantage for clients across Europe and beyond. The site includes: "The opening of this facility marks an important milestone in our mission to accelerate the development and manufacturing of transformative cell and gene therapies globally," said Dr. Orla Cloak, Chief Executive Officer of Minaris Advanced Therapies. "It enhances our European footprint and enhances our ability to meet client needs with speed, quality, and scalability." "This facility embodies our shared vision for the future of cell and gene therapy manufacturing—scalable, flexible, and globally integrated," said Iain Baird, Chairman of the Board, Minaris Advanced Therapies. "The seamless transition into this new facility is a testament to the dedication of our team in Germany and the commitment Minaris Advanced Therapies has to bring long-term value to clients and patients worldwide." Minaris hosted an opening celebration at the new site on Thursday, July 31. About Minaris Advanced Therapies Minaris Advanced Therapies is a global contract development and manufacturing organization and contract testing provider with a focus on cell and gene therapies. Minaris Advanced Therapies is headquartered in Philadelphia, Pennsylvania, and has more than 650,000 square feet of infrastructure across the United States, Europe and Asia. The organization has manufactured and released over 7,500 GMP batches and has a global network that supports therapy developers through early-stage development, clinical trials and commercial manufacturing. Minaris Advanced Therapies is a portfolio company of Altaris. About Altaris Altaris is an investment firm with an exclusive focus on acquiring and building companies in the healthcare industry. Since its inception in 2003, Altaris has invested in more than 50 companies across a range of healthcare sub-sectors, with a consistent goal of delivering value to the healthcare system and generating attractive financial returns for investors. Altaris is headquartered in New York City and manages $10 billion of equity capital. For more information, please visit